Sponsors (3)
The bill improves government visibility into foreign ownership risks to pharmaceutical supply chains—helping prevent drug shortages and strengthen oversight—while imposing administrative costs, risking disclosure of sensitive details, and potentially discouraging beneficial foreign investment.
Patients who depend on prescription drugs (and hospitals/health systems that serve them) will get earlier identification of pharmaceutical supply‑chain concentration risks, helping prevent or mitigate drug shortages and protect treatment continuity.
Federal agencies (FTC, HHS, FDA and CFIUS) will receive annual, detailed data on foreign ownership and its effects on pharmaceutical and related supply chains, improving government oversight, policy responses, and regulatory coordination.
Taxpayers and policymakers gain greater transparency about CFIUS reviews of pharmaceutical and DNA‑related transactions, which may deter risky foreign investments and strengthen national security oversight.
Hospitals, state governments, and patients could face reduced foreign capital inflows if increased scrutiny discourages investment, potentially slowing expansion of domestic manufacturing capacity and raising costs or limiting supply growth.
Public summaries of findings risk revealing sensitive commercial or security information (e.g., sequencing capacity, mitigation measures), which could harm hospitals and patients if not carefully redacted.
Preparing and producing annual, detailed reports will increase workload and administrative costs for the FTC and CFIUS, with those costs borne by taxpayers and by diverting agency resources.
Based on analysis of 2 sections of legislative text.
Requires the FTC (with CFIUS) to produce an initial and then annual reports assessing foreign investment impacts on U.S. drug manufacturing, supply chains, and DNA sequencing/storage capacity and to publish an unclassified summary.
Official title: Require the Federal Trade Commission to submit a report on foreign investment in the pharmaceutical industry of the United States, and for other purposes.
Introduced July 15, 2026 by Elizabeth Warren · Last progress July 15, 2026
Requires the Federal Trade Commission, working with Treasury/CFIUS, to produce an initial report within one year and then annual reports on foreign investment in the U.S. pharmaceutical sector. The reports must assess supply-chain concentration and reliance on foreign manufacturing, impacts on domestic capacity to produce drugs and drug ingredients, and effects of foreign investment in DNA sequencing or storage technologies, and must enumerate and summarize prior CFIUS reviews related to these topics.